- Home
- DOMH vs CERO Comparison
DOMH vs CERO Comparison
Compare DOMH & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- CERO
- Stock Information
- Founded
- DOMH 1967
- CERO 2017
- Country
- DOMH United States
- CERO United States
- Employees
- DOMH N/A
- CERO N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- DOMH Health Care
- CERO
- Exchange
- DOMH Nasdaq
- CERO Nasdaq
- Market Cap
- DOMH 8.8M
- CERO 8.4M
- IPO Year
- DOMH N/A
- CERO N/A
- Fundamental
- Price
- DOMH $1.35
- CERO $2.23
- Analyst Decision
- DOMH
- CERO
- Analyst Count
- DOMH 0
- CERO 0
- Target Price
- DOMH N/A
- CERO N/A
- AVG Volume (30 Days)
- DOMH 70.1K
- CERO 872.3K
- Earning Date
- DOMH 11-08-2024
- CERO 02-20-2025
- Dividend Yield
- DOMH N/A
- CERO N/A
- EPS Growth
- DOMH N/A
- CERO N/A
- EPS
- DOMH N/A
- CERO N/A
- Revenue
- DOMH $12,589,000.00
- CERO N/A
- Revenue This Year
- DOMH N/A
- CERO N/A
- Revenue Next Year
- DOMH N/A
- CERO N/A
- P/E Ratio
- DOMH N/A
- CERO N/A
- Revenue Growth
- DOMH 1117.50
- CERO N/A
- 52 Week Low
- DOMH $0.83
- CERO $2.04
- 52 Week High
- DOMH $3.20
- CERO $1,280.00
- Technical
- Relative Strength Index (RSI)
- DOMH 55.06
- CERO 32.20
- Support Level
- DOMH $1.00
- CERO $2.21
- Resistance Level
- DOMH $1.29
- CERO $2.58
- Average True Range (ATR)
- DOMH 0.12
- CERO 1.04
- MACD
- DOMH 0.05
- CERO 0.10
- Stochastic Oscillator
- DOMH 84.21
- CERO 2.30
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.